2C-B-morpholine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
2C-B-morpholine, also known as 2C-B-norphenmetrazine or as 2-(4-bromo-2,5-dimethoxyphenyl)morpholine, is a serotonin receptor modulator of the phenylmorpholine (phenmetrazine) and cyclized phenethylamine groups.[1] It is a ligand of the serotonin 5-HT2A receptor, with an affinity of 20.6 nM and an Emax of 4%.[1] The drug showed 103-fold lower affinity for this receptor than R(–)-DOB and had minimal agonist activity (with R(–)-DOB having an Emax of 51% in the assay), so for practical purposes would act as an antagonist at the 5-HT2A receptor under most circumstances, despite being technically classified as a partial agonist.[1] 2C-B-morpholine was first described in the scientific literature by Richard Glennon and colleagues by 2004.[1]
- None
- In general Unscheduled.
| Clinical data | |
|---|---|
| Other names | 2C-B-Norphenmetrazine; 2-(4-Bromo-2,5-dimethoxyphenyl)morpholine; 2C-B-MOR; 2C-B-Mor |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor ligand |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C12H16BrNO3 |
| Molar mass | 302.168 g·mol−1 |
| 3D model (JSmol) | |
| |
| |